Results 71 to 80 of about 737 (141)

Data_Sheet_1_Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19.pdf [PDF]

, 2023
IntroductionThe SARS-CoV-2 outbreak has threatened the human population globally as the numbers of reinfection cases even after large-scale vaccination.
Pingsheng Lei (5240192), Renato Martins da Silva (14787250), Paula Gebe Abreu Cabral (6515375), Antônio Brazil Viana Junior (14787268), Raul Ferraz Arruda (14787253), Sávio Bastos de Souza (6700298), Arícia Leone Evangelista Monteiro de Assis (14787259), Yolanda Porto Muniz Martins (14787262), Junbiao Chang (1523644), Sheila Passos de Figueiredo Cabral (14787256), Carlos Augusto de Araújo Tavares (14787265)   +10 more
core   +1 more source

Clinical Characteristics and Treatment Efficacy in Patients With SARS‐CoV‐2 Positivity After Nirmatrelvir‐Ritonavir Therapy

Journal of Medical Virology, Volume 97, Issue 5, May 2025.
ABSTRACT Nirmatrelvir‐ritonavir (NMV‐r) has been widely used to treat coronavirus disease 2019 (COVID‐19) for a standard period of 5‐days. However, there are increasing reports of patients with persistent severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) positivity after the standard 5‐day course of NMV‐r treatment.
Huqin Yang, Leyi Gao, Yi Xue, Zhijin Zhang, Lujia Guan, Haifan Zhang, Haomiao Ma, Xuyan Li, Jieqiong Li, Zhaohui Tong   +9 more
wiley   +1 more source

DataSheet_1_Coinfection of SARS-CoV-2 and influenza A (H3N2) detected in bronchoalveolar lavage fluid of a patient with long COVID using metagenomic next−generation sequencing: a case report.pdf [PDF]

, 2023
The growing number of long COVID cases has drawn clinical attention to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has been spreading worldwide since winter 2019. Its symptoms are not limited to fatigue and shortness of breath but
Yajuan Zhang (838924), Xuefei Liang (16917174), Linlin Wang (289071), Qiushi Wang, Qiushi Wang (417314), Jia Liu (41593), Xuefei Liang, Jing Ma, Jing Ma (24574), Yajuan Zhang, Yang Yu, Yang Yu (4292), Meng Wang (124646), Linlin Wang, Jia Liu, Meng Wang   +15 more
core   +1 more source

Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis

PLOS ONE
Objective The aim of this study was to assess the effectiveness and safety of azvudine in treating coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). Methods A search was carried out in PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar until October 20, 2023.
Bahman Amani, Behnam Amani
openaire   +2 more sources

Clinical Characteristics of SARS‐COV‐2 Omicron Variant in Acute Myeloid Leukemia and Acute Lymphocytic Leukemia Patients: A Multi‐Center Retrospective Study

Cancer Reports, Volume 8, Issue 4, April 2025.
ABSTRACT Background The death rate of hematological malignancies is high, and the death rate of patients with COVID‐19 infection is further increased. Although there have been expert consensus and relevant guidelines to introduce the recommendations of the guidelines for patients with hematological malignancies complicated with COVID‐19 infection ...
Lin Wang, Ruihua Mi, Lin Chen, Jia Liu, Haiping Yang, Meng Hu, Zhao Xiaoqiang, Yan Zhang, Xiaobing Xu, Bing Liu, Hongmian Zhao, Li Qianyu, Tao Liu, Chen Zhenzhu, Jinxiao Yao, Ying Yang, Xudong Wei   +16 more
wiley   +1 more source

Characteristics of COVID-19 (Delta Variant)/HIV Co-infection: A Cross-sectional Study in Henan Province, China [PDF]

, 2022
BACKGROUND: Since the end of July 2021, SARS-CoV-2 (Delta variant) invaded Henan Province, China, causing a rapid COVID-19 spread in the province. Among them, the clinical features of COVID-19 (Delta Variant)/HIV co-infection have attracted our attention.
Zhang, Guojun, Guojun Zhang, Jianjun Gou, Rui Yang, Li, Jing, Cheng, Jiuling, Jiuling Cheng, Huaqi Wang, Wang, Huaqi, Jing Li, Song, Xiangjin, Yuanwei Pan, Yang, Rui, Gou, Jianjun, Xudong He, Pan, Yuanwei, He, Xudong, Xiangjin Song   +17 more
core   +1 more source

Effectiveness and Safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the Treatment of Moderate to Severe COVID‐19

Immunity, Inflammation and Disease, Volume 13, Issue 4, April 2025.
This is the first study comparing the effectiveness of simnotrelvir/ritonavir and nirmatrelvir/ritonavir in treating moderate and severe COVID‐19 patients. Patients who received simnotrelvir/ritonavir exhibited shorter hospitalization. Disease progression, viral clearance times, and symptom resolution time were similar between the two groups.
Xin Chen, Xiao‐Qing Lin, Fang Cheng, Shi‐Lin Zheng, Qiang Zhang, Te Wu, Xian‐Gao Jiang, Ji‐Chan Shi   +7 more
wiley   +1 more source

Construction of Minigenome Replicon of Nipah Virus and Investigation of Biological Activity. [PDF]

Viruses
Nipah virus (NiV), a highly lethal zoonotic pathogen causing encephalitis and respiratory diseases with mortality rates up to 40–70%, faces research limitations due to its strict biosafety level 4 (BSL-4) containment requirements, hindering ...
Wang F, Chen R, Zhong J, Zhou A, Peng R, Xue B, Zhou Y, Tang J, Chen X, Yang Q.   +9 more
europepmc   +2 more sources

Effectiveness of the antiviral medications azvudine and nirmatrelvir-ritonavir in treating COVID-19 in patients with hematological malignancies. [PDF]

Clinics (Sao Paulo)
Background: Patients with Hematological Malignancies (HM) are at a high risk of mortality from Coronavirus disease 2019 (COVID-19). The available antivirals were different between China and other countries.
Zeng Z, Li F, Zhong M, Zhu L, Chen W, Wang X.   +5 more
europepmc   +2 more sources

A Retrospective Analysis of Azvudine in Patients with COVID-19 and Pre-existing Cancer

Journal of Cancer
Objectives: Azvudine has been recommended as a potential treatment for the recently discovered Coronavirus disease (COVID-19) in 2019. However, the effectiveness of Azvudine in individuals who have both COVID-19 and pre-existing cancer remains uncertain.
Li, Fangyu, Zheng, Keao, Qi, Xueyan, Cui, Kaixia, Yang, Jing, Hao, Zhiying   +5 more
openaire   +2 more sources